References
- Ferlay J. Globocan 2000: Cancer incidence, mortality, and prevalence worldwide. Lyon: IARC Press; 2001: 1 CD-ROM.
- Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
- Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004; 72: 61-77.
- Kufe DW, Holland JF, Frei E, Abramson DH, Dang CT, DeAngelis LM, et al. Cancer medicine 6. Hamilton, Ont.: BC Decker; 2003.
- Barletta C, Scillato F, Sega FM, Mannella E. Genetic alteration in gastrointestinal cancer. A molecular and cytogenetic study. Anticancer Res 1993; 136A: 2325-9.
- Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004; 157: 327-49.
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827): 1039-43.
- Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103(7): 2316-21.
- Uen YH, Lin SR, Wu CH, Hsieh JS, Lu CY, Yu FJ, et al. Clinical significance of MUC1 and c-Met RT-PCR detection of circulating tumor cells in patients with gastric carcinoma. Clin Chim Acta 2006; 367(1-2): 55-61.
- Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005; 11(6): 84-92.
- Felsher DW. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 2003; 3(5): 375-80.
- Kataoka H, Joh T, Kasugai K, Okayama N, Moriyama A, Asai K, et al. Expression of mRNA for heregulin and its receptor, ErbB-3 and ErbB-4, in human upper gastrointestinal mucosa. Life Sci 1998; 63(7): 553-64.
- Bachmair F, Huber C, Daxenbichler G. Quanititation of gene expression by means of HPLC analysis of RT-PCR products. Clin Chim Acta 1999; 279(1-2): 25-34.
- Huber CG. Micropellicular stationary phases for high-performance liquid chromatography of double-stranded DNA. J Chromatogr A 1998; 806: 3-30.
- Heideman DA, Snijders PJ, Bloemena E, Meijer CJ, Offerhaus GJ, Meuwissen SG, et al. Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J Pathol 2001; 194(4): 428-35.
- Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85(9): 1894-902.
- Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, et al. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene 2007; 26(7): 1078-87.
- Bianco C, Adkins HB, Wechselberger C, Seno M, Normanno N, De Luca A, et al. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol 2002; 22(8): 2586-97.
- Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, et al. Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res 2006; 12(17): 5158-64.
- Hamada S, Watanabe K, Hirota M, Bianco C, Strizzi L, Mancino M, et al. beta-Catenin/TCF/LEF regulate expression of the short form human Cripto-1. Biochem Biophys Res Commun 2007; 355(1): 240-4.
- Minchiotti G. Nodal-dependant Cripto signaling in ES cells: from stem cells to tumor biology. Oncogene 2005; 24(37): 5668-75.
- Haruma K, Ito M, Kohmoto K, Kamada T, Kitada Y, Yasui W, et al. Expression of cell cycle regulators and growth factor/receptor systems in gastric carcinoma in young adults: association with Helicobacter pylori infection. Int J Mol Med 2000; 5(2): 185-90.
- Akama Y, Yasui W, Yokozaki H, Kuniyasu H, Kitahara K, Ishikawa T, et al. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res 1995; 86(7): 617-21.
- Tenderenda M. A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res 2005; 24(3): 405-14.
- Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8(2): 86-94.
- Yu J, Miehlke S, Ebert MP, Szokodi D, Wehvnignh B, Malfertheiner P, et al. Expression of cyclin genes in human gastric cancer and in first degree relatives. Chin Med J (Engl) 2002; 115(5): 710-5.
- Breuleux M. Role of heregulin in human cancer. Cell Mol Life Sci 2007; 64(18): 2358-77.
- Kobayashi M, Iwamatsu A, Shinohara-Kanda A, Ihara S, Fukui Y. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 2003; 22(9): 1294-301.
- Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M, et al. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res 1998; 18(4A): 2727-32.